Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease

NCT06964230 is registered in ClinicalTrials.gov with T3D Therapeutics, Inc. as lead sponsor.

NCT NCT06964230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06964230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
Lead sponsor
T3D Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 26, 2026
Completion date
June 30, 2031
Enrollment
376 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease